Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Clinical impact of genetic and molecular markers in myelodysplastic syndromes (MDS)

Clinical impact of genetic and molecular markers in myelodysplastic syndromes (MDS) Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid neoplasms defined by morphologic dysplasia, peripheral cytopenia, and clonal instability with enhanced risk to transform into secondary acute myeloid leukaemia (AML). The prognosis and clinical picture in MDS vary depending on the variant of disease, cell types affected and genes involved in the malignant process. In fact, more and more data suggest that cytogenetic and molecular defects and gene-variants are associated with the clinical course and prognosis. The current article provides a short summary of our knowledge about molecular and genetic markers in MDS, with special reference to their potential prognostic and therapeutic implications. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Clinical impact of genetic and molecular markers in myelodysplastic syndromes (MDS)

Loading next page...
 
/lp/springer-journals/clinical-impact-of-genetic-and-molecular-markers-in-myelodysplastic-EavIYyW7tW
Publisher
Springer Journals
Copyright
Copyright © 2009 by Springer-Verlag
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-009-0098-6
Publisher site
See Article on Publisher Site

Abstract

Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid neoplasms defined by morphologic dysplasia, peripheral cytopenia, and clonal instability with enhanced risk to transform into secondary acute myeloid leukaemia (AML). The prognosis and clinical picture in MDS vary depending on the variant of disease, cell types affected and genes involved in the malignant process. In fact, more and more data suggest that cytogenetic and molecular defects and gene-variants are associated with the clinical course and prognosis. The current article provides a short summary of our knowledge about molecular and genetic markers in MDS, with special reference to their potential prognostic and therapeutic implications.

Journal

memo - Magazine of European Medical OncologySpringer Journals

Published: Jan 1, 2009

References